Key Drivers
- Low Leverage
- Heavy Cash Burn
- Ongoing Dilution
AIAI Summary
GRAL is a clinical-evidence and reimbursement option—not a proven growth story—so investors should treat the FDA review as a catalyst while requiring evidence that Galleri can convert self-pay volume growth into payer coverage, lower cash burn, and sustainable economics before underwriting durable upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Low Leverage
- •Heavy Cash Burn
- •Ongoing Dilution
GRAL has low leverage and strong liquidity, but severe losses, cash burn, dilution, and a rising valuation despite negative fundamentals make the investment case high risk.
Price Behavior
Key Price Behavior Insights:
- •Recent rebound
- •Key resistance
- •Critical support
Over the last month, GRAL rebounded to $80.77 but remains range-bound below $82.50 resistance, with $75–$76 support critical to preserving its cautious bullish bias.
Sharp rebound from $75.11 to $80.77 in two sessions signals elevated volatility
Sentiment & News
Key News Insights:
- •FDA Meeting
- •Investor Interest
- •Insider Sale
GRAIL advances Galleri's regulatory and investor profile through an upcoming FDA meeting and healthcare conference, though insider selling adds a cautious note.
Regulatory progress could be a key near-term catalyst for GRAIL, while the CFO share sale may temper sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings